Watching the clock: Endoplasmic reticulum-mediated control of circadian rhythms in cancer

Annals of Medicine

Volumn 46, Issue 4, 2014, Pages 233-243

  Pluquet, Olivier ^a   Dejeans, Nicolas ^b   Chevet, Eric ^b  

^a UNIV LILLE   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Angiogenesis; ATF6; Cancer; Circadian clock; Endoplasmic reticulum; IRE1; PER1; PERK; Stress; Tumor

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 6; PROTEIN IRE1;

ARTICLE; CANCER INCIDENCE; CARCINOGENESIS; CIRCADIAN RHYTHM; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; HOMEOSTASIS; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR CLOCK; PATHOPHYSIOLOGY; PRIORITY JOURNAL; SOMATIC MUTATION; UNFOLDED PROTEIN RESPONSE; ANIMAL; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; CIRCADIAN CLOCKS; CIRCADIAN RHYTHM; ENDOPLASMIC RETICULUM; ENDOPLASMIC RETICULUM STRESS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84902191074     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2013.874664     Document Type: Article

References (156)

1. Kozutsumi Y, Segal M, Normington K, Gething MJ, Sambrook J. The presence of malfolded proteins in the endoplasmic reticulum signals the induction of glucose-regulated proteins. Nature. 1988; 332: 462-4.
2. Walter P, Ron D. The unfolded protein response: from stress pathway to homeostatic regulation. Science. 2011; 334: 1081-6.
3. Calfon M, Zeng H, Urano F, Till JH, Hubbard SR, Harding HP, et al. IRE1 couples endoplasmic reticulum load to secretory capacity by processing the XBP-1 mRNA. Nature. 2002; 415: 92-6.
4. Lee K, Tirasophon W, Shen X, Michalak M, Prywes R, Okada T, et al. IRE1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes Dev. 2002; 16: 452-66.
5. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. X BP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001; 107: 881-91.
6. Acosta-Alvear D, Zhou Y, Blais A, Tsikitis M, Lents NH, Arias C, et al. XBP1 controls diverse cell type- and condition-specific transcriptional regulatory networks. Mol Cell. 2007; 27: 53-66.
7. Lee A-H, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol. 2003; 23: 7448-59.
8. Hetz C. The unfolded protein response: controlling cell fate decisions under ER stress and beyond. Nat Rev Mol Cell Biol. 2012; 13: 89-102.
9. Urano F, Wang X, Bertolotti A, Zhang Y, Chung P, Harding HP, et al. Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1. Science. 2000; 287: 664-6.
10. Han D, Lerner AG, Vande Walle L, Upton J-P, Xu W, Hagen A, et al. IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates. Cell. 2009; 138: 562-75.
11. Hollien J, Lin JH, Li H, Stevens N, Walter P, Weissman JS. Regulated Ire1-dependent decay of messenger RNAs in mammalian cells. J Cell Biol. 2009; 186: 323-31.
12. Hollien J, Weissman JS. Decay of endoplasmic reticulum-localized mRNAs during the unfolded protein response. Science. 2006; 313: 104-7.
13. Oikawa D, Tokuda M, Hosoda A, Iwawaki T. Identification of a consensus element recognized and cleaved by IRE1 alpha. Nucleic Acids Res. 2010; 38: 6265-73.
14. Upton JP, Wang L, Han D, Wang ES, Huskey NE, Lim L, et al. IRE1alpha cleaves select microRNAs during ER stress to derepress translation of proapoptotic Caspase-2. Science. 2012; 338: 818-22.
15. Dai BH, Geng L, Wang Y, Sui CJ, Xie F, Shen RX, et al. micro RNA-199a-5p protects hepatocytes from bile acid-induced sustained endoplasmic reticulum stress. Cell Death Dis. 2013; 4: e604.
16. Maurel M, Chevet E. Endoplasmic reticulum stress signaling: the micro- RNA connection. Am J Physiol Cell Physiol. 2013; 304: C1117-26.
17. Maurel M, Dejeans N, Taouji S, Chevet E, Grosset CF. MicroRNA-1291- mediated silencing of IRE1alpha enhances Glypican-3 expression. RNA. 2013; 19: 778-88.
18. Kimata Y, Kohno K. Endoplasmic reticulum stress-sensing mechanisms in yeast and mammalian cells. Curr Opin Cell Biol. 2011; 23: 135-42.
19. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol. 2000; 2: 326-32.
20. Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, et al. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell. 2000; 6: 1099-108.
21. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell. 2003; 11: 619-33.
22. Lerner AG, Upton JP, Praveen PV, Ghosh R, Nakagawa Y, Igbaria A, et al. IRE1alpha induces thioredoxin-interacting protein to activate the NLRP3 inflammasome and promote programmed cell death under irremediable ER stress. Cell Metab. 2012; 16: 250-64.
23. Novoa I, Zeng H, Harding HP, Ron D. Feedback inhibition of the unfolded protein response by GADD34-mediated dephosphorylation of eIF2alpha. J Cell Biol. 2001; 153: 1011-22.
24. Haze K, Yoshida H, Yanagi H, Yura T, Mori K. Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress. Mol Biol Cell. 1999; 10: 3787-99.
25. Asada R, Kanemoto S, Kondo S, Saito A, Imaizumi K. The signalling from endoplasmic reticulum-resident bZIP transcription factors involved in diverse cellular physiology. J Biochem. 2011; 149: 507-18.
26. Yamamoto K, Sato T, Matsui T, Sato M, Okada T, Yoshida H, et al. Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1. Dev Cell. 2007; 13: 365-76.
27. Shoulders MD, Ryno LM, Genereux JC, Moresco JJ, Tu PG, Wu C, et al. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep. 2013; 3: 1279-92.
28. Credle JJ, Finer-Moore JS, Papa FR, Stroud RM, Walter P. On the mechanism of sensing unfolded protein in the endoplasmic reticulum. Proc Natl Acad Sci U S A. 2005; 102: 18773-84.
29. Gardner BM, Walter P. Unfolded proteins are Ire1-activating ligands that directly induce the unfolded protein response. Science. 2011; 333: 1891-4.
30. Oikawa D, Kitamura A, Kinjo M, Iwawaki T. Direct association of unfolded proteins with mammalian ER stress sensor, IRE1beta. PloS One. 2012; 7: e51290.
31. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446: 153-8.
32. Koong AC, Chauhan V, Romero-Ramirez L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol Ther. 2006; 5: 756-9.
33. Romero-Ramirez L, Cao H, Nelson D, Hammond E, Lee A-H, Yoshida H, et al. XBP1 is essential for survival under hypoxic conditions and is required for tumor growth. Cancer research. 2004; 64: 5943-7.
34. Hetz C, Martinon F, Rodriguez D, Glimcher LH. The unfolded protein response: integrating stress signals through the stress sensor IRE1alpha. Physiol Rev. 2011; 91: 1219-43.
35. Mimura N, Fulciniti M, Gorgun G, Tai YT, Cirstea D, Santo L, et al. Blockade of XBP1 splicing by inhibition of IRE1alpha is a promising therapeutic option in multiple myeloma. Blood. 2012; 119: 5772-81.
36. Papandreou I, Denko NC, Olson M, Van Melckebeke H, Lust S, Tam A, et al. Identification of an Ire1alpha endonuclease specific inhibitor with cytotoxic activity against human multiple myeloma. Blood. 2011; 117: 1311-4.
37. Auf G, Jabouille A, Guerit S, Pineau R, Delugin M, Bouchecareilh M, et al. Inositol-requiring enzyme 1alpha is a key regulator of angiogenesis and invasion in malignant glioma. Proc Natl Acad f Sci U S A. 2010; 107: 15553-8.
38. Dejeans N, Pluquet O, Lhomond S, Grise F, Bouchecareilh M, Juin A, et al. Autocrine control of glioma cells adhesion and migration through IRE1alpha-mediated cleavage of SPARC mRNA. J Cell Sci. 2012; 125(Pt 18): 4278-87.
39. Pluquet O, Dejeans N, Bouchecareilh M, Lhomond S, Pineau R, Higa A, et al. Posttranscriptional regulation of PER1 underlies the oncogenic function of IREalpha. Cancer Res. 2013; 73: 4732-43.
40. Healy SJM, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. Eur J Pharmacol. 2009; 625: 234-46.
41. Koumenis C. ER stress, hypoxia tolerance and tumor progression. Curr Mol Med. 2006; 6: 55-69.
42. Rouschop KM, Dubois LJ, Keulers TG, van den Beucken T, Lambin P, Bussink J, et al. PERK/eIF2alpha signaling protects therapy resistant hypoxic cells through induction of glutathione synthesis and protection against ROS. Proc Natl Acad Sci U S A. 2012; 110: 4622-7.
43. Blais JD, Addison CL, Edge R, Falls T, Zhao H, Wary K, et al. Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress. Mol Cell Biol. 2006; 26: 9517-32.
44. Corazzari M, Lovat PE, Armstrong JL, Fimia GM, Hill DS, Birch-Machin M, et al. Targeting homeostatic mechanisms of endoplasmic reticulum stress to increase susceptibility of cancer cells to fenretinide-induced apoptosis: the role of stress proteins ERdj5 and ERp57. Br J Cancer. 2007; 96: 1062-71.
45. Bi M, Naczki C, Koritzinsky M, Fels D, Blais J, Hu N, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J. 2005; 24: 3470-81.
46. Jaramillo MC, Zhang DD. The emerging role of the Nrf2-Keap1 signaling pathway in cancer. Genes Dev. 2013; 27: 2179-91.
47. Lau A, Villeneuve NF, Sun Z, Wong PK, Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res. 2008; 58: 262-70.
48. Hetz C, Chevet E, Harding HP. Targeting the unfolded protein response in disease. Nat Rev Drug Discov. 2013; 12: 703-19.
49. Arai M, Kondoh N, Imazeki N, Hada A, Hatsuse K, Kimura F, et al. Transformation-associated gene regulation by ATF6alpha during hepatocarcinogenesis. FEBS Lett. 2006; 580: 184-90.
50. Shuda M, Kondoh N, Imazeki N, Tanaka K, Okada T, Mori K, et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol. 2003; 38: 605-14.
51. Schewe DM, Aguirre-Ghiso JA. ATF6alpha-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo. Proc Natl Acad Sci U S A. 2008; 105: 10519-24.
52. Panda S, Hogenesch JB, Kay SA. Circadian rhythms from flies to human. Nature. 2002; 417: 329-35.
53. Reppert SM, Weaver DR. Coordination of circadian timing in mammals. Nature. 2002; 418: 935-41.
54. Sahar S, Sassone-Corsi P. Metabolism and cancer: the circadian clock connection. Nat Rev Cancer. 2009; 9: 886-96.
55. Hardin PE. Essential and expendable features of the circadian timekeeping mechanism. Curr Opin Neurobiol. 2006; 16: 686-92.
56. Preitner N, Damiola F, Lopez-Molina L, Zakany J, Duboule D, Albrecht U, et al. The orphan nuclear receptor REV-ERBalpha controls circadian transcription within the positive limb of the mammalian circadian oscillator. Cell. 2002; 110: 251-60.
57. Mehra A, Baker CL, Loros JJ, Dunlap JC. Post-translational modifications in circadian rhythms. Trends Biochem Sci. 2009; 34: 483-90.
58. Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, et al. Coordinated transcription of key pathways in the mouse by the circadian clock. Cell. 2002; 109: 307-20.
59. Storch K-F, Lipan O, Leykin I, Viswanathan N, Davis FC, Wong WH, et al. Extensive and divergent circadian gene expression in liver and heart. Nature. 2002; 417: 78-83.
60. Evans JA, Davidson AJ. Health consequences of circadian disruption in humans and animal models. Prog Mol Biol Transl Sci. 2013; 119: 283-323.
61. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst. 2001; 93: 1557-62.
62. Kubo T, Ozasa K, Mikami K, Wakai K, Fujino Y, Watanabe Y, et al. Prospective cohort study of the risk of prostate cancer among rotatingshift workers: findings from the Japan collaborative cohort study. Am J Epidemiol. 2006; 164: 549-55.
63. Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, et al. Night-shift work and risk of colorectal cancer in the nurses' health study. J Natl Cancer Inst. 2003; 95: 825-8.
64. Viswanathan AN, Hankinson SE, Schernhammer ES. Night shift work and the risk of endometrial cancer. Cancer Res. 2007; 67: 10618-22.
65. Straif K, Baan R, Grosse Y, Secretan BA, El Ghissassi F, Bouvard VR, et al. Carcinogenicity of shift-work, painting, and fire-fighting. Lancet Oncol. 2007; 8: 1065-6.
66. Stevens RG. Light-at-night, circadian disruption and breast cancer: assessment of existing evidence. Int J Epidemiol. 2009; 38: 963-70.
67. Fu L, Kettner NM. The circadian clock in cancer development and therapy. Prog Mol Biol Transl Sci. 2013; 119: 221-82.
68. Chu LW, Zhu Y, Yu K, Zheng T, Yu H, Zhang Y, et al. Variants in circadian genes and prostate cancer risk: a population-based study in China. Prostate Cancer Prostatic Dis. 2008; 11: 342-8.
69. Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, et al. The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast Cancer Res Treat. 2011; 127: 531-40.
70. Hoffman AE, Yi C-H, Zheng T, Stevens RG, Leaderer D, Zhang Y, et al. CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res. 2010; 70: 1459-68.
71. Hoffman AE, Zheng T, Stevens RG, Ba Y, Zhang Y, Leaderer D, et al. Clock-cancer connection in non-Hodgkin's lymphoma: a genetic association study and pathway analysis of the circadian gene cryptochrome 2. Cancer Res. 2009; 69: 3605-13.
72. Zhu Y, Brown HN, Zhang Y, Stevens RG, Zheng T. Period3 structural variation: a circadian biomarker associated with breast cancer in young women. Cancer Epidemiol Biomarkers Prev. 2005; 14: 268-70.
73. Zhu Y, Stevens RG, Leaderer D, Hoffman A, Holford T, Zhang Y, et al. Non-synonymous polymorphisms in the circadian gene NPAS2 and breast cancer risk. Breast Cancer Res Treat. 2008; 107: 421-5.
74. Zienolddiny S, Haugen A, Lie J-AS, Kjuus H, Anmarkrud KH, Kjærheim K. Analysis of polymorphisms in the circadian-related genes and breast cancer risk in Norwegian nurses working night shift s. Breast Cancer Res. 2013; 15: R53.
75. Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, et al. Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res. 2009; 69: 9315-22.
76. Madden MH, Anic GM, Thompson RC, Nabors LB, Olson JJ, Browning JE, et al. Circadian pathway genes in relation to glioma risk and outcome. Cancer Causes Control. 2014; 25: 25-32.
77. Chen S-T, Choo K-B, Hou M-F, Yeh K-T, Kuo S-J, Chang J-G. Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis. 2005; 26: 1241-6.
78. Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006; 22: 375-82.
79. Winter SL, Bosnoyan-Collins L, Pinnaduwage D, Andrulis IL. Expression of the circadian clock genes Per1 and Per2 in sporadic and familial breast tumors. Neoplasia. 2007; 9: 797-800.
80. Gery S, Gombart AF, Yi WS, Koeffler C, Hofmann W-K, Koeffler HP. Transcription profiling of C/EBP targets identifies Per2 as a gene implicated in myeloid leukemia. Blood. 2005; 106: 2827-36.
81. Lin Y-M, Chang JH, Yeh K-T, Yang M-Y, Liu T-C, Lin S-F, et al. Disturbance of circadian gene expression in hepatocellular carcinoma. Mol Carcinog. 2008; 47: 925-33.
82. Yeh K-T, Yang M-Y, Liu T-C, Chen J-C, Chan W-L, Lin S-F, et al. Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol. 2005; 206: 111-20.
83. Pogue-Geile KL, Lyons-Weiler J, Whitcomb DC. Molecular overlap of fly circadian rhythms and human pancreatic cancer. Cancer Lett. 2006; 243: 55-7.
84. Hsu C-M, Lin S-F, Lu C-T, Lin P-M, Yang M-Y. Altered expression of circadian clock genes in head and neck squamous cell carcinoma. Tumour Biol. 2012; 33: 149-55.
85. Yang M-Y, Yang W-C, Lin P-M, Hsu J-F, Hsiao H-H, Liu Y-C, et al. Altered expression of circadian clock genes in human chronic myeloid leukemia. J Biol Rhythms. 2011; 26: 136-48.
86. Mazzoccoli G, Panza A, Valvano MR, Palumbo O, Carella M, Pazienza V, et al. Clock gene expression levels and relationship with clinical and pathological features in colorectal cancer patients. Chronobiol Int. 2013; 28: 841-51.
87. Oshima T, Takenoshita S, Akaike M, Kunisaki C, Fujii S, Nozaki A, et al. Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep. 2011; 25: 1439-46.
88. Xia HC, Niu ZF, Ma H, Cao SZ, Hao SC, Liu ZT, et al. Deregulated expression of the Per1 and Per2 in human gliomas. Can J Neurol Sci. 2010; 37: 365-70.
89. Lengyel Z, Lovig C, Kommedal S, Keszthelyi R, Szekeres Gr, Battyani Z, et al. Altered expression patterns of clock gene mRNAs and clock proteins in human skin tumors. Tumour Biol. 2013; 34: 811-19.
90. Mazzoccoli G, Piepoli A, Carella M, Panza A, Pazienza V, Benegiamo G, et al. Altered expression of the clock gene machinery in kidney cancer patients. Biomed Pharmacother. 2012; 66: 175-9.
91. Relles D, Sendecki J, Chipitsyna G, Hyslop T, Yeo CJ, Arafat HA. Circadian gene expression and clinicopathologic correlates in pancreatic cancer. J Gastrointest Surg. 2013; 17: 443-50.
92. Luo Y, Wang F, Chen L-A, Chen X-W, Chen Z-J, Liu P-F, et al. Deregulated expression of cry1 and cry2 in human gliomas. Asian Pac J Cancer Prev. 2012; 13: 5725-8.
93. Hanoun M, Eisele L, Suzuki M, Greally JM, Huttmann A, Aydin S, et al. Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. PLoS One. 2012; 7: e34347.
94. Tokunaga H, Takebayashi Y, Utsunomiya H, Akahira J-I, Higashimoto M, Mashiko M, et al. Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand. 2008; 87: 1060-70.
95. Karantanos T, Theodoropoulos G, Gazouli M, Vaiopoulou A, Karantanou C, Lymberi M, et al. Expression of clock genes in patients with colorectal cancer. Int J Biol Markers. 2013; 28: 280-5.
96. Yu H, Meng X, Wu J, Pan C, Ying X, Zhou Y, et al. Cryptochrome 1 overexpression correlates with tumor progression and poor prognosis in patients with colorectal cancer. PLoS One. 2013; 8: e61679.
97. Valekunja UK, Edgar RS, Oklejewicz M, van der Horst GTJ, O'Neill JS, Tamanini F, et al. Histone methyltransferase MLL3 contributes to genome-scale circadian transcription. Proc Natl Acad Sci U S A. 2013; 110: 1554-9.
98. Kuo S-J, Chen S-T, Yeh K-T, Hou M-F, Chang Y-S, Hsu NC, et al. Disturbance of circadian gene expression in breast cancer. Virchows Arch. 2009; 454: 467-74.
99. Taniguchi H, Fernandez AF, Setien F, Ropero S, Ballestar E, Villanueva A, et al. Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res. 2009; 69: 8447-54.
100. Yang M-Y, Chang J-G, Lin P-M, Tang K-P, Chen Y-H, Lin HY-H, et al. Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci. 2006; 97: 1298-307.
101. Alhopuro P, Bjorklund M, Sammalkorpi H, Turunen M, Tuupanen S, Bistrom M, et al. Mutations in the circadian gene CLOCK in colorectal cancer. Mol Cancer Res. 2010; 8: 952-60.
102. Sjoblom T, Jones SN, Wood LD, Parsons DW, Lin J, Barber TD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268-74.
103. Gu X, Xing L, Shi G, Liu Z, Wang X, Qu Z, et al. The circadian mutation PER2(S662G) is linked to cell cycle progression and tumorigenesis. Cell Death Differ. 2012; 19: 397-405.
104. Wood PA, Yang X, Hrushesky WJM. Clock genes and cancer. Integr Cancer Ther. 2009; 8: 303-8.
105. Sotak M, Polidarova L, Ergang P, Sumova A, Pacha J. An association between clock genes and clock-controlled cell cycle genes in murine colorectal tumors. Int J Cancer. 2013; 132: 1032-41.
106. Filipski E, King VM, Li X, Granda TG, Mormont M-C, Claustrat B, et al. Disruption of circadian coordination accelerates malignant growth in mice. Pathol Biol (Paris). 2003; 51: 216-19.
107. Logan RW, Zhang C, Murugan S, O'Connell S, Levitt D, Rosenwasser AM, et al. Chronic shift-lag alters the circadian clock of NK cells and promotes lung cancer growth in rats. J Immunol. 2012; 188: 2583-91.
108. Filipski E, Subramanian P, Carriere J, Guettier C, Barbason H, Levi F. Circadian disruption accelerates liver carcinogenesis in mice. Mutat Res. 2009; 680: 95-105.
109. Hastings MH. Circadian clocks: self-assembling oscillators? Curr Biol. 2003; 13: R681-2.
110. Fu L, Pelicano H, Liu J, Huang P, Lee C. The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002; 111: 41-50.
111. Lee S, Donehower LA, Herron AJ, Moore DD, Fu L. Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS One. 2010; 5: e10995.
112. Ozturk N, Lee JH, Gaddameedhi S, Sancar A. Loss of cryptochrome reduces cancer risk in p53 mutant mice. Proc Natl Acad Sci U S A. 2009; 106: 2841-6.
113. Antoch MP, Gorbacheva VY, Vykhovanets O, Toshkov IA, Kondratov RV, Kondratova AA, et al. Disruption of the circadian clock due to the Clock mutation has discrete effects on aging and carcinogenesis. Cell Cycle. 2008; 7: 1197-204.
114. Yasuniwa Y, Izumi H, Wang K-Y, Shimajiri S, Sasaguri Y, Kawai K, et al. Circadian disruption accelerates tumor growth and angio/ stromagenesis through a Wnt signaling pathway. PLoS One. 2010; 5: e15330.
115. Hwang-Verslues WW, Chang P-H, Jeng Y-M, Kuo W-H, Chiang P-H, Chang Y-C, et al. Loss of corepressor PER2 under hypoxia up-regulates OCT1-mediated EMT gene expression and enhances tumor malignancy. Proc Natl Acad Sci U S A. 2013; 110: 12331-6.
116. Geusz ME, Blakely KT, Hiler DJ, Jamasbi RJ. Elevated mPer1 gene expression in tumor stroma imaged through bioluminescence. Int J Cancer. 2010; 126: 620-30.
117. Zheng B, Albrecht U, Kaasik K, Sage M, Lu W, Vaishnav S, et al. Nonredundant roles of the mPer1 and mPer2 genes in the mammalian circadian clock. Cell. 2001; 105: 683-94.
118. Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, et al. Arole for the clock gene per1 in prostate cancer. Cancer Res. 2009; 69: 7619-25.
119. Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, Virk RK, et al. Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res. 2007; 13: 1399-404.
120. Mostafaie N, Kallay E, Sauerzapf E, Bonner E, Kriwanek S, Cross HS, et al. Correlated downregulation of estrogen receptor beta and the circadian clock gene Per1 in human colorectal cancer. Mol Carcinog. 2009; 48: 642-7.
121. Sato F, Nagata C, Liu Y, Suzuki T, Kondo J, Morohashi S, et al. PERIOD1 is an anti-apoptotic factor in human pancreatic and hepatic cancer cells. J Biochem. 2009; 146: 833-8.
122. Yang X, Wood PA, Ansell CM, Quiton DFT, Oh E-Y, Du-Quiton J, et al. The circadian clock gene Per1 suppresses cancer cell proliferation and tumor growth at specific times of day. Chronobiol Int. 2009; 26: 1323-39.
123. Lee CC. Tumor suppression by the mammalian Period genes. Cancer Causes Control. 2006; 17: 525-30.
124. Hua H, Wang Y, Wan C, Liu Y, Zhu B, Yang C, et al. Circadian gene mPer2 overexpression induces cancer cell apoptosis. Cancer Sci. 2006; 97: 589-96.
125. Yang X, Wood PA, Ansell CM, Ohmori M, Oh E-Y, Xiong Y, et al. Beta-catenin induces beta-TrCP-mediated PER2 degradation altering circadian clock gene expression in intestinal mucosa of ApcMin/+ mice. J Biochem. 2009; 145: 289-97.
126. Yang X, Wood PA, Oh E-Y, Du-Quiton J, Ansell CM, Hrushesky WJM. Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat. 2009; 117: 423-31.
127. Jung-Hynes B, Huang W, Reiter RJ, Ahmad N. Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res. 2010; 49: 60-8.
128. Sun C-M, Huang S-F, Zeng J-M, Liu D-B, Xiao Q, Tian W-J, et al. Per2 inhibits k562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction. Pathol Oncol Res. 2010; 16: 403-11.
129. Oda A, Katayose Y, Yabuuchi S, Yamamoto K, Mizuma M, Shirasou S, et al. Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin. Anticancer Res. 2009; 29: 1201-9.
130. Miyazaki K, Wakabayashi M, Hara Y, Ishida N. Tumor growth suppression in vivo by overexpression of the circadian component, PER2. Genes Cells. 2010; 15: 351-8.
131. Gery S, Virk RK, Chumakov K, Yu A, Koeffler HP. The clock gene Per2 links the circadian system to the estrogen receptor. Oncogene. 2007; 26: 7916-20.
132. Chedid A, Nair V. Diurnal rhythm in endoplasmic reticulum of rat liver: electron microscopic study. Science. 1972; 175: 176-9.
133. Labrecque G, Soulban G. Biological rhythms in the physiology and pharmacology of blood coagulation. Chronobiol Int. 1991; 8: 361-72.
134. Reddy AB, Karp NA, Maywood ES, Sage EA, Deery M, O'Neill JS, et al. Circadian orchestration of the hepatic proteome. Curr Biol. 2006; 16: 1107-15.
135. Edgar RS, Green EW, Zhao Y, van Ooijen G, Olmedo M, Qin X, et al. Peroxiredoxins are conserved markers of circadian rhythms. Nature. 2012; 485: 459-64.
136. O'Neill JS, Reddy AB. Circadian clocks in human red blood cells. Nature. 2011; 469: 498-503.
137. O'Neill JS, Reddy AB. The essential role of cAMP/Ca2+ signalling in mammalian circadian timekeeping. Biochem Soc Trans. 2012; 40: 44-50.
138. Ikeda M, Sugiyama T, Wallace CS, Gompf HS, Yoshioka T, Miyawaki A, et al. Circadian dynamics of cytosolic and nuclear Ca2+ in single suprachiasmatic nucleus neurons. Neuron. 2003; 38: 253-63.
139. Baez-Ruiz A, Diaz-Munoz M. Chronic inhibition of endoplasmic reticulum calcium-release channels and calcium-ATPase lengthens the period of hepatic clock gene Per1. J Circadian Rhythms. 2011; 9: 6.
140. Hatori M, Hirota T, Iitsuka M, Kurabayashi N, Haraguchi S, Kokame K, et al. Light-dependent and circadian clock-regulated activation of sterol regulatory element-binding protein, X-box-binding protein 1, and heat shock factor pathways. Proc Natl Acad Sci U S A. 2011; 108: 4864-9.
141. Vollmers C, Gill S, DiTacchio L, Pulivarthy SR, Le HD, Panda S. Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. Proc Natl Acad Sci U S A. 2009; 106: 21453-8.
142. Igarashi T, Izumi H, Uchiumi T, Nishio K, Arao T, Tanabe M, et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene. 2007; 26: 4749-60.
143. Koyanagi S, Hamdan AM, Horiguchi M, Kusunose N, Okamoto A, Matsunaga N, et al. cAMP-response element (CRE)-mediated transcription by activating transcription factor-4 (ATF4) is essential for circadian expression of the Period2 gene. J Biol Chem. 2011; 286: 32416-23.
144. Wu J, Rutkowski DT, Dubois M, Swathirajan J, Saunders T, Wang J, et al. ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress. Dev Cell. 2007; 13: 351-64.
145. Cretenet G, Le Clech M, Gachon F. Circadian clock-coordinated 12 Hr period rhythmic activation of the IRE1alpha pathway controls lipid metabolism in mouse liver. Cell Metab. 2010; 11: 47-57.
146. Hughes ME, DiTacchio L, Hayes KR, Vollmers C, Pulivarthy S, Baggs JE, et al. Harmonics of circadian gene transcription in mammals. PLoS Genet. 2009; 5: e1000442.
147. Senovilla L, Vitale I, Martins I, Tailler M, Pailleret C, Michaud M, et al. An immunosurveillance mechanism controls cancer cell ploidy. Science. 2012; 337: 1678-84.
148. Hart LS, Cunningham JT, Datta T, Dey S, Tameire F, Lehman SL, et al. ER stress-mediated autophagy promotes Myc-dependent transformation and tumor growth. J Clin Invest. 2012; 122: 4621-34.
149. De Raedt T, Walton Z, Yecies JL, Li D, Chen Y, Malone CF, et al. Exploiting cancer cell vulnerabilities to develop a combination therapy for ras-driven tumors. Cancer Cell. 2011; 20: 400-13.
150. Huber A-L, Lebeau J, Guillaumot P, Petrilli V, Malek M, Chilloux J, et al. p58IPK-mediated attenuation of the pro-apoptotic PERK-CHOP pathway allows malignant progression upon low glucose. Mol Cell. 2013; 49: 1049-59.
151. Qing G, Li B, Vu A, Skuli N, Walton ZE, Liu X, et al. ATF4 regulates MYC-mediated neuroblastoma cell death upon glutamine deprivation. Cancer Cell. 2012; 22: 631-44.
152. Gaddameedhi S, Selby CP, Kaufmann WK, Smart RC, Sancar A. Control of skin cancer by the circadian rhythm. Proc Natl Acad Sci U S A. 2011; 108: 18790-5.
153. Li XM, Mohammad-Djafari A, Dumitru M, Dulong S, Filipski E, Siffroi-Fernandez S, et al. Acircadian clock transcription model for the personalization of cancer chronotherapy. Cancer Res. 2013; 73: 7176-88.
154. Karbovskyi LL, Minchenko DO, Garmash IaA, Minchenko OG. [Molecular mechanisms of circadian clock functioning]. Ukr Biokhim Zh. 2011; 83: 5-24. [In Ukrainian]
155. Nogueira TC, Lellis-Santos C, Jesus DS, Taneda M, Rodrigues SC, Amaral FG, et al. Absence of melatonin induces night-time hepatic insulin resistance and increased gluconeogenesis due to stimulation of nocturnal unfolded protein response. Endocrinology. 2011; 152: 1253-63.
156. Ushijima K, Koyanagi S, Sato Y, Ogata T, Matsunaga N, Fujimura A, et al. Role of activating transcription factor-4 in 24-hour rhythm of serotonin transporter expression in the mouse midbrain. Mol Pharmacol. 2012; 82: 264-70.